NewAmsterdam Pharma Co N.V. (NAMS) Financials
Annual revenue, profitability and per-share results for NewAmsterdam Pharma Co N.V., as reported in SEC filings.
Revenue • FY2025
$22.5M
▼ 50.6%YoY
Net income • FY2025
-$203.82M
▲ 15.6%YoY
Diluted EPS • FY2025
-$1.72
▲ 32.8%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $22.5M | -$203.82M | — | -$1.72 | -$148.03M | -1002.9% | -50.6% |
| FY2024 | $45.56M | -$241.6M | — | -$2.56 | -$159.24M | -386.9% | +223.4% |
| FY2023 | $14.09M | -$176.94M | — | -$2.15 | -$141.24M | -1298.6% | -86.3% |
Figures as reported in NewAmsterdam Pharma Co N.V.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a NAMS filing.
Get an email when NAMS files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.